Elusys' anthrax product approaches market
This article was originally published in Scrip
Private US biotech firm Elusys Therapeutics has proved its antitoxin inhalational anthrax treatment obiltoxaximab in three Phase III studies, paving the way for a BLA filing, the company says.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.